TDMS Study 91005-08 Pathology Tables
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
FINAL #1 MICE
Facility: Southern Research Institute
Chemical CAS #: 7220-79-3
Lock Date: 09/05/03
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 9 5 2 6
Moribund Sacrifice 7 4 5 1
Accidently Killed 1
Dosing Accident 1 1
Survivors
Terminal Sacrifice 29 40 41 41
Natural Death 2 1 2
Moribund Sacrifice 2
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Gallbladder (42) (45) (47) (44)
Intestine Large, Cecum (43) (46) (47) (44)
Intestine Small, Duodenum (43) (45) (47) (42)
Carcinoma 1 (2%)
Intestine Small, Jejunum (43) (45) (47) (43)
Adenoma 1 (2%)
Intestine Small, Ileum (43) (44) (47) (43)
Liver (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 5 (10%) 4 (8%) 3 (6%)
Hepatocellular Adenoma 11 (22%) 15 (30%) 13 (26%) 9 (18%)
Hepatocellular Adenoma, Multiple 4 (8%) 4 (8%) 9 (18%) 4 (8%)
Histiocytic Sarcoma 2 (4%)
Serosa, Fibrosarcoma, Metastatic, Skin 1 (2%)
Mesentery (18) (14) (15) (13)
Fibrosarcoma 1 (8%)
Fibrosarcoma, Metastatic, Skin 1 (7%) 1 (7%) 1 (8%)
Histiocytic Sarcoma 1 (6%) 1 (8%)
Leiomyosarcoma, Metastatic, Uterus 1 (8%)
Rhabdomyosarcoma, Metastatic, Skin 1 (7%)
Rhabdomyosarcoma, Metastatic, Uncertain
Page 2
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Primary Site 1 (6%)
Pancreas (46) (46) (49) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (49)
Stomach, Forestomach (50) (50) (50) (49)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (45) (47) (50) (46)
Carcinoma 1 (2%)
Tooth (2) (10) (3) (3)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Fibrosarcoma, Metastatic, Skin 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%) 2 (4%)
Islets, Pancreatic (46) (47) (49) (48)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (46) (49) (48) (47)
Pars Distalis, Adenoma 1 (2%) 7 (14%) 5 (10%) 3 (6%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (46) (50) (49) (47)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Tissue NOS (3) (3)
Abdominal, Histiocytic Sarcoma 1 (33%)
Thoracic, Histiocytic Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48) (50) (46) (48)
Ovary (47) (48) (49) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cystadenoma 2 (4%) 3 (6%) 3 (6%) 2 (4%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 1 (2%)
Oviduct (1)
Uterus (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Polyp Stromal 2 (4%) 2 (4%)
Vagina (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (7) (5) (10) (10)
Iliac, Fibrosarcoma, Metastatic, Skin 1 (20%)
Iliac, Histiocytic Sarcoma 1 (14%)
Inguinal, Fibrosarcoma, Metastatic, Skin 1 (14%)
Inguinal, Histiocytic Sarcoma 1 (14%)
Mediastinal, Histiocytic Sarcoma 1 (14%) 1 (10%)
Page 4
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Pancreatic, Fibrosarcoma, Metastatic, Skin 1 (20%)
Pancreatic, Histiocytic Sarcoma 1 (14%)
Pancreatic, Leiomyosarcoma, Metastatic,
Uterus 1 (10%)
Popliteal, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (10%)
Lymph Node, Mandibular (48) (49) (48) (46)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (46) (49) (49) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (47) (47) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (43) (47) (44) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 2 (4%) 1 (2%) 2 (4%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 3 (6%) 2 (4%) 2 (4%) 2 (4%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Leiomyosarcoma,
Metastatic, Uterus 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Rhabdomyosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Cranium, Osteosarcoma 1 (2%)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (1) (4) (3) (3)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
Fibrosarcoma, Metastatic, Skin 1 (25%) 1 (33%) 1 (33%)
Hemangioma 1 (33%)
Page 5
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Leiomyosarcoma, Metastatic, Uterus 1 (33%)
Rhabdomyosarcoma 2 (50%) 2 (67%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 3 (6%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Nose (50) (50) (50) (50)
Trachea (49) (50) (50) (49)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (43) (48) (47) (47)
Harderian Gland (49) (50) (50) (50)
Adenoma 4 (8%) 2 (4%) 7 (14%) 3 (6%)
Carcinoma 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (45) (47) (49) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymphoma Malignant 6 (12%) 4 (8%) 9 (18%) 12 (24%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 36 40 37
Total Primary Neoplasms 60 57 72 57
Total Animals with Benign Neoplasms 25 29 32 22
Total Benign Neoplasms 30 41 48 29
Total Animals with Malignant Neoplasms 25 15 18 24
Total Malignant Neoplasms 30 16 24 28
Total Animals with Metastatic Neoplasms 5 4 5 5
Total Metastatic Neoplasm 8 11 8 11
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 11 6 5 3
Moribund Sacrifice 4 4 7 4
Accidently Killed 1
Dosing Accident 1 2
Survivors
Terminal Sacrifice 35 38 38 41
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (40) (44) (45) (44)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (45) (46) (46) (47)
Carcinoma 1 (2%)
Intestine Small, Duodenum (42) (46) (46) (46)
Adenoma 1 (2%) 2 (4%)
Carcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (45) (45) (47) (47)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 2 (4%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (43) (45) (44) (47)
Carcinoma 1 (2%)
Liver (50) (50) (50) (49)
Carcinoma, Metastatic, Pancreas 1 (2%)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 2 (4%) 5 (10%) 3 (6%) 1 (2%)
Hepatoblastoma 2 (4%) 2 (4%) 2 (4%)
Hepatocellular Carcinoma 11 (22%) 9 (18%) 8 (16%) 11 (22%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%) 3 (6%) 3 (6%)
Hepatocellular Adenoma 14 (28%) 20 (40%) 14 (28%) 14 (29%)
Hepatocellular Adenoma, Multiple 14 (28%) 13 (26%) 12 (24%) 13 (27%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mesentery (5) (11) (5) (4)
Page 9
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Carcinoma, Metastatic, Pancreas 1 (25%)
Hemangiosarcoma 2 (18%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (9%)
Histiocytic Sarcoma 1 (20%)
Pancreas (48) (50) (49) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Acinus, Carcinoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (48)
Squamous Cell Papilloma 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (50) (50) (48)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Subcapsular, Adenoma 5 (10%) 4 (8%) 2 (4%) 5 (10%)
Adrenal Medulla (48) (50) (50) (48)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Benign 1 (2%) 2 (4%)
Islets, Pancreatic (50) (50) (49) (48)
Adenoma 2 (4%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thyroid Gland (50) (50) (49) (48)
Follicular Cell, Adenoma 3 (6%) 1 (2%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1)
Epididymis (50) (50) (49) (49)
Carcinoma, Metastatic, Pancreas 1 (2%)
Seminal Vesicle (49) (50) (50) (49)
Carcinoma 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (5) (3) (3) (6)
Bronchial, Carcinoma, Metastatic, Pancreas 1 (17%)
Iliac, Histiocytic Sarcoma 1 (33%)
Mediastinal, Carcinoma, Metastatic,
Harderian Gland 1 (20%)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (17%)
Mediastinal, Histiocytic Sarcoma 1 (33%)
Pancreatic, Histiocytic Sarcoma 1 (33%)
Renal, Histiocytic Sarcoma 1 (33%)
Lymph Node, Mandibular (43) (46) (48) (47)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Lymph Node, Mesenteric (47) (50) (48) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
Spleen (49) (50) (49) (48)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 4 (8%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Fibroma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Page 11
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Osteoma 1 (2%)
Osteosarcoma 1 (2%)
Cranium, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
Vertebra, Hemangiosarcoma 1 (2%)
Skeletal Muscle (4) (1) (1)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (100%)
Hemangiosarcoma, Multiple 1 (25%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (25%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 9 (18%) 5 (10%) 8 (16%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 4 (8%) 4 (8%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 4 (8%) 3 (6%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hepatoblastoma, Metastatic,
Liver 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Page 12
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (45) (49) (49) (47)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Harderian Gland (50) (50) (50) (50)
Adenoma 7 (14%) 1 (2%) 11 (22%) 5 (10%)
Carcinoma 2 (4%) 4 (8%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Bilateral, Adenoma 1 (2%)
Bilateral, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (48) (50) (50) (48)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%)
Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 91005-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLENE BLUE TRIHYDRATE Date: 04/26/05
Route: GAVAGE Time: 09:25:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 12.5 25
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 47 46 47
Total Primary Neoplasms 87 90 96 89
Total Animals with Benign Neoplasms 37 38 39 35
Total Benign Neoplasms 56 53 61 53
Total Animals with Malignant Neoplasms 26 23 25 26
Total Malignant Neoplasms 31 37 35 36
Total Animals with Metastatic Neoplasms 5 6 5 6
Total Metastatic Neoplasm 11 16 7 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------